Gunderson Dettmer advised TeneoTwo on the deal. TeneoTwo, a developer of therapeutic antibodies, announced its pending acquisition by AstraZeneca, a bio-pharmaceutical company that focuses on the discovery,...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here